GLP-1 and GIP drugs in fat cells

A June 2026 review in Pharmacological Research asks a question the weight-loss headlines tend to skip: what do GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists actually do inside human fat cells^[1]? The answer matters because tirzepatide and semaglutide are prescribed to millions, yet most of what we know about their effects on adipose tissue still comes from rodent models rather than human adipocyte studies.

Weight loss is the visible part of a larger metabolic shift

GLP-1 receptor agonists such as semaglutide and dual GIPR/GLP-1R agonists such as tirzepatide clearly reduce body weight. The SURMOUNT-1 trial reported a mean 20.9% reduction at 72 weeks on tirzepatide 15 mg^[2]. But the Curto et al. review argues that appetite suppression and caloric deficit only partially explain what these drugs do. Both drug classes appear to alter lipid metabolism, glucose uptake, and inflammatory signaling within the fat cell itself. In animal models, GLP-1R activation has been linked to changes in lipolysis (the breakdown of stored fat), thermogenesis (heat production in adipose tissue), and adipokine secretion (the chemical signals fat cells send to other organs).

The dual agonist angle is what makes tirzepatide particularly interesting in this context. GIP receptors are expressed on adipocytes, and the GIP arm of tirzepatide may contribute to fat-tissue effects that a GLP-1-only drug does not produce. GIP signaling in fat tissue has been associated with lipid storage, blood-flow regulation in adipose depots, and adiponectin release. Whether those pathways explain the larger weight-loss numbers seen in head-to-head trials, or whether they shape body composition differently, is still an open question. The review notes that teasing apart the GIP contribution from the GLP-1 contribution in a dual agonist is methodologically difficult, especially when most published work uses whole-animal rather than isolated-cell approaches.

The gap: most data come from mice, not human cells

The central finding of the Curto et al. review is a methodological gap. The authors surveyed the published literature on incretin-based drugs and adipose tissue and found that the majority of mechanistic studies relied on murine cell lines or rodent models^[1]. Human adipocyte data are sparse. This matters because mouse and human fat cells differ in receptor expression, metabolic rate, and hormonal response profiles. A finding that GLP-1R activation boosts thermogenesis in a mouse brown-fat cell does not automatically translate to a human subcutaneous white-fat depot.

The authors conclude that future research should prioritize human-derived cell models, including primary adipocytes isolated from surgical biopsies and iPSC-derived fat cells grown in the lab, to build a mechanistic picture that clinicians can actually use. Without that work, the field is left extrapolating from species whose fat biology differs in receptor density, depot distribution, and metabolic rate.

Why this matters beyond the lab

Understanding how these drugs reshape fat-cell metabolism has practical downstream consequences. If tirzepatide's GIP arm drives specific adipocyte effects (improved insulin sensitivity within the fat depot, reduced inflammatory cytokine output, or preferential loss of visceral over subcutaneous fat), those mechanisms could eventually inform which patients benefit most from a dual agonist rather than a GLP-1-only drug. They could also clarify whether stopping the drug reverses those tissue-level changes or whether some metabolic remodeling persists. The SURMOUNT-4 discontinuation data already showed that weight returns after stopping tirzepatide^[3]. Participants in the placebo switch-over arm regained 14.0% of body weight between week 36 and week 88, while those who continued tirzepatide lost a further 5.5%. Whether the metabolic reprogramming at the adipocyte level also reverses on that timeline is unknown.

For now, the clinical takeaway is modest: we know these drugs work for weight loss, glycaemic control, and (in tirzepatide's case) obstructive sleep apnea^[4]. We do not yet know, in human tissue, exactly how they change the biology of fat itself. The Curto et al. review is a call for that research, not a delivery of it.

What we do not yet know

Several questions remain unanswered. Does tirzepatide's GIP receptor activity produce adipocyte effects that semaglutide does not? Do these drugs change the ratio of visceral to subcutaneous fat, and does that shift persist after discontinuation? Are the metabolic changes in fat cells the same across ethnicities, sexes, and age groups? The review also notes that obesity is increasingly understood as a disease with distinct adipose-tissue phenotypes, and that lumping all patients into one category may hide the very differences these drugs exploit.

Until researchers run controlled studies in human adipocytes and human adipose-tissue biopsies, these remain open questions. If you are considering tirzepatide or another GLP-1 drug, these mechanistic gaps do not change the clinical evidence for weight loss and glycaemic control. They do mean the full story of how these drugs work in your body is still being written. For a broader view of tirzepatide's trial programme and regulation, see our peptide page.